Vertex Pharmaceuticals Inc / Ma (VRTX) Capital Expenditures (2009 - 2026)

Vertex Pharmaceuticals (VRTX) has reported Capital Expenditures for 18 consecutive years, with $133.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures rose 227.76% year-over-year to $133.4 million; the TTM figure through Mar 2026 stood at $530.3 million (up 96.41% YoY), while the FY2025 annual figure was $437.6 million, up 46.99% from the prior year.
• Capital Expenditures came in at $133.4 million for Q1 2026 at Vertex Pharmaceuticals, down from $149.4 million in the prior quarter.
• The five-year high for Capital Expenditures was $149.4 million in Q4 2025, with the low at $33.6 million in Q4 2022.
• Average Capital Expenditures over 5 years is $74.9 million, with a median of $63.6 million recorded in 2022.
• Across the five-year window, Capital Expenditures tumbled 45.63% in 2022 and soared 227.76% in 2026, its largest moves.
• Year by year, Capital Expenditures stood at $33.6 million in 2022, then jumped by 72.92% to $58.1 million in 2023, then surged by 59.38% to $92.6 million in 2024, then surged by 61.34% to $149.4 million in 2025, then declined by 10.71% to $133.4 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $133.4 million, $149.4 million, and $101.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.